Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | ACACB | O00763 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17281109 | 0.89 | KMT2A (0.43) | KMT2AMAPTACACBMEN1HPGD | |
| SCHEMBL123415 | 0.88 | MAPT (0.55) | KMT2AMAPTACACBMEN1HPGD | |
| SCHEMBL14579975 | 0.86 | KMT2A (0.50) | KMT2AMAPTMEN1POLBKDM4E | |
| SCHEMBL8047267 | 0.83 | ACACB (0.50) | KMT2AMAPTACACBMEN1HPGD | |
| SCHEMBL20969625 | 0.83 | MAPT (0.46) | KMT2AMAPTACACBMEN1HPGD | |
| SCHEMBL24974017 | 0.83 | MAPT (0.46) | KMT2AMAPTACACBMEN1HPGD | |
| SCHEMBL24974023 | 0.83 | MAPT (0.46) | KMT2AMAPTACACBMEN1HPGD | |
| SCHEMBL14831640 | 0.83 | MAPT (0.46) | KMT2AMAPTACACBMEN1HPGD | |
| SCHEMBL18888181 | 0.83 | ACACB (0.46) | KMT2AMAPTACACBMEN1HPGD | |
| SCHEMBL24352243 | 0.83 | LMNA (0.64) | KMT2AMAPTMEN1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-25 | — | — | US | disclosed |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11377422-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2021156636-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | KING'S COLLEGE LONDON (GB) | 2021-08-12 | — | — | WO | disclosed |
| US-8916565-B2 | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140256936-A1 | DIARYLETHENE COMPOUNDS AND USES THEREOF | SWITCH MATERIALS, INC. (CA) | 2014-09-11 | — | — | US | disclosed |
| US-20140179743-A1 | NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140105921-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | ONYX THERAPEUTICS, INC. | 2014-04-17 | — | — | US | disclosed |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-08-02 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8198318-B2 | Therapeutic amides | ALLERGEN, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-7985767-B2 | Glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; carboxy-functional amides or sulfonamide and carboxy bioisosteres thereof; 5-(-3-(N-(4-(1-hydroxyhexyl)phenyl)acetamido)butyl)thiophene-2-carboxylic acid for example | ALLERGAN, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-20090239858-A1 | THERAPEUTIC AMIDES | ALLERGAN, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20080119539-A1 | THERAPEUTIC AMIDES | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140105921-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | PREP, VIP, PEPD | KMT2A 2378/4885MAPT 3880/4885ACACB 1295/4885 |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | KMT2A 4328/4885MAPT 2718/4885ACACB 1694/4885 |
| US-20080119539-A1 | THERAPEUTIC AMIDES | GOT2, GOT1, ARG2 | KMT2A 3404/4885MAPT 2061/4885ACACB 64/4885 |
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | KMT2A 1913/4885MAPT 4060/4885ACACB 1093/4885 |
| US-20140179743-A1 | NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) | MAPK1, MAP3K1, MAP3K20 | KMT2A 3434/4885MAPT 3850/4885ACACB 2189/4885 |
| US-20090239858-A1 | THERAPEUTIC AMIDES | ACER2, SLC10A1, ASAH2 | KMT2A 2295/4885MAPT 1981/4885ACACB 268/4885 |
| US-11377422-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | KMT2A 2429/4885MAPT 1799/4885ACACB 2850/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | KMT2A 3837/4885MAPT 4883/4885ACACB 4063/4885 |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ5, KCNJ1 | KMT2A 2577/4885MAPT 2311/4885ACACB 1576/4885 |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | M6PR, ASGR1, IGF2R | KMT2A 4507/4885MAPT 3700/4885ACACB 3569/4885 |
| US-20140256936-A1 | DIARYLETHENE COMPOUNDS AND USES THEREOF | KCNH2, KCNH3, SCN2B | KMT2A 1512/4885MAPT 4557/4885ACACB 3548/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | KMT2A 3568/4885MAPT 1451/4885ACACB 3098/4885 |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | TRPV1, TRPA1, TRPV2 | KMT2A 2763/4885MAPT 2258/4885ACACB 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.